key: cord-0708787-c70fw174
authors: Pang, Kai; Jin, Lan; Zhang, Zhongtao
title: Systematic application of COVID-19 nucleic acid tests in general surgery departments in China: an update of current status with nationwide survey data - Correspondence
date: 2020-08-19
journal: Int J Surg
DOI: 10.1016/j.ijsu.2020.08.011
sha: 48e91dee3f724c690f880514bd6e74029dd9cc9a
doc_id: 708787
cord_uid: c70fw174

nan

Nucleic acid test has now become a primary approach for the screening of the COVID-19 virus in China for its high availability and quick result. It was one of the primary diagnosing methods according to the latest version of the Chinese Protocol of COVID-19 Diagnosis and Management [1] , and has also become the key component in our current daily surgical workflow [2, 3] .

Nowadays (Jul. 20, 2020), as far as Beijing Municipality are concerned, almost all hospitals inside the city require a recent negative nucleic acid test for a patient to be ward-admitted via surgical outpatient, which serves as part of our governmental effort to "conduct medical activities in the new normal circumstances (of COVID-19)". To get a clear and whole picture on the current application of nucleic acid test in the daily workflow of surgical departments across China, we conducted an online survey within our nationwide surgical community. A total of 1010 general surgeons from 589 hospitals responded to the survey in the first 48 hours since it was open on Jul. 5, 2020. Of all the respondents, 75% were from outside of Beijing and 25% from inside; By personal ranks 47% were chief surgeons, 27% were associate chief surgeons, and the other 26% were attendings and residents; By hospital size 87% respondents were from Class 3 hospitals (medical centers) and 13% from Class 1 or 2 hospitals (smaller hospitals). After initial analysis on the distribution of answers, we excluded answers from respondents who were the sole participant of his/her hospital, that is to say, only if a hospital has two or more surgeons participating in our survey would then the hospital be included in our in-depth analysis, so that we can assess the credibility of the answers by the in-hospital consistency.

The results from the survey were displayed in Table 1 , in which the protocols in different clinical scenarios all turned out in line with the current protocols that was strictly observed in Beijing hospitals, suggesting that hospitals across the country are more or less on the same page when adapting to the COVID-19 new normal. Considering the fact that 0 confirmed COVID-19 cases was ever discovered in all surgical departments within Beijing City, these measures might therefore be useful for colleagues around the world, despite the fact that we cannot be so sure about this "zero infection" outcome in other parts of the country. To summarize the surveyed current situation in China, majority of hospitals are equipped with a specialized fever clinic and majority of them are open 24 hours a day; majority of patients presenting fever in surgical outpatients and surgical ERs will receive mandatory COVID-19 screening (by nucleic acid test, pulmonary CT or other measures); majority of post-operative fevers will receive COVID-19 screening, where nucleic acid tests are mostly not mandatory and instead simpler measures (e.g. routine blood test) are more often applied; majority of hospitals require a negative nucleic acid test for each admission through outpatient; a small proportion (9%) of hospitals do not require a negative nucleic acid test for each admission through surgical ER though, yet most of these surgical departments set up buffer ward rooms for emergency/critical admissions; majority of nucleic acid tests across the country were conducted by throat swabs rather than nasal swabs.

Provenance and peer review Not Commissioned, internally reviewed J o u r n a l P r e -p r o o f 

National Health Commission of the People's Republic of China

Surgeons' response to COVID-19: modified workflow to adapt to the new normal

Optimizing response in surgical systems during and after COVID-19 pandemic: lessons from China and the UK -Perspective

The following additional information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories, then this should be stated. 

Please enter the name of the registry, the hyperlink to the registration and the unique identifying number of the study. You can register your research at http://www.researchregistry.com to obtain your UIN if you have not already registered your study. This is mandatory for human studies only.1. Name of the registry: na 2. Unique Identifying number or registration ID: na 3. Hyperlink to your specific registration (must be publicly accessible and will be checked): na

Please specify the contribution of each author to the paper, e.g. study design, data collections, data analysis, writing. Others, who have contributed in other ways should be listed as contributors.K.P: study design, data analysis, writing L.J : data analysis,consultation Z.Z: study design, data collections

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. Please note that providing a guarantor is compulsory.

J o u r n a l P r e -p r o o fAll research data are available via reasonable email request towards the correspondent author.